Drug-eluting stent

Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients

Retrieved on: 
Wednesday, June 30, 2021
Medical devices, Interventional radiology, Interventional cardiology, Stent, Drug-eluting stent

In addition, XIENCE stents recently received CE Mark approval for DAPT as short as 28 days giving XIENCE stents the shortest DAPT indication in the world.

Key Points: 
  • In addition, XIENCE stents recently received CE Mark approval for DAPT as short as 28 days giving XIENCE stents the shortest DAPT indication in the world.
  • In addition to the HBR indication, Abbott has also received FDA approval and European CE Mark approval for its next-generation XIENCE Skypoint stent.
  • "The new FDA approval for DAPT for the XIENCE family of stents provides interventional cardiologists confidence they are delivering the best care to patients with high bleeding risk.
  • With the shortest approved DAPT labeling, Abbott's XIENCE stents can help physicians treat their HBR patients more effectively.

Philips announces first patient enrollment in DEFINE GPS global multicenter study to assess superiority of PCI procedures guided by co-registered iFR and interventional angiography

Retrieved on: 
Tuesday, June 22, 2021
Medicine, Clinical medicine, Cardiovascular system, Interventional cardiology, Medical devices, Percutaneous coronary intervention, Angioplasty, Coronary stent, Cardiology, Drug-eluting stent, Instantaneous wave-free ratio

DEFINE GPS is a follow-up to the DEFINE PCI study [1] a one-year trial sponsored by Philips that evaluated the potential of treating residual ischemia in order to improve clinical outcomes for coronary stent patients.

Key Points: 
  • DEFINE GPS is a follow-up to the DEFINE PCI study [1] a one-year trial sponsored by Philips that evaluated the potential of treating residual ischemia in order to improve clinical outcomes for coronary stent patients.
  • With DEFINE GPS we will be able to definitively determine if a physiology-based PCI approach results in superior patient outcomes compared to standard angioplasty.
  • The DEFINE GPS study is sponsored by Philips, with the Cardiovascular Research Foundation overseeing core lab and clinical event committee activities.
  • The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.

Worldwide Drug-Eluting Stents Industry to 2027 - Surge in Demand for Minimally Invasive Surgical Procedures is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Surgery, Health, Medical devices, Interventional cardiology, Medicine, Medical technology, Drug-eluting stent, Medical devices, Clinical medicine, Stent, Bare-metal stent, Percutaneous coronary intervention

Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.

Key Points: 
  • Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.
  • Polymer-based drug-eluting coating stents are designed to allow consistent and controlled release of drug from stent surface into arteries.
  • Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
  • Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.

Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Retrieved on: 
Thursday, April 22, 2021
Health, Medical devices, Surgery, Clinical trials, Research, Science, Cardiology, Medicine, Clinical medicine, Interventional cardiology, Carbonyl compounds, Drug-eluting stent, Medical devices, Interventional radiology, Everolimus, Stent, Randomized controlled trial, Paclitaxel

b'Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany.

Key Points: 
  • b'Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany.
  • The BIOADAPTOR RCT is evaluating the DynamX\xe2\x84\xa2 Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.\nThe BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx\xe2\x84\xa2, a leading drug-eluting stent (DES).
  • The company\xe2\x80\x99s mission is to transform the care of patients with heart and vascular disease through innovation.\nThe DynamX Coronary Bioadaptor System is CE Mark approved.
  • Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice.

According to THE SAGE GROUP, Restenosis Remains a Significant and Costly Problem After Endovascular Treatment of Peripheral Artery Disease (PAD)

Retrieved on: 
Tuesday, March 16, 2021
Science, Research, Pharmaceutical, Surgery, Health, Consulting, Professional services, Other Health, Medical specialties, Medicine, Clinical medicine, Interventional radiology, Interventional cardiology, Cardiology, Restenosis, Surgery, Angioplasty, Drug-eluting stent, Medical devices, Stent

The cost of restenosis after treatment with percutaneous transluminal angioplasty (PTA) is $364-$728 million, stated Mary L. Yost, President of THE SAGE GROUP.

Key Points: 
  • The cost of restenosis after treatment with percutaneous transluminal angioplasty (PTA) is $364-$728 million, stated Mary L. Yost, President of THE SAGE GROUP.
  • New technologies, drug-coated balloons (DCBs) and drug-eluting stents (DES), have decreased restenosis and reduced longer-term revascularization costs.
  • Even with the availability of new drug-coated devices, restenosis remains a major, costly problem, Ms. Yost stated.
  • THE SAGE GROUP, a research and consulting company, specializes in PAD, Intermittent Claudication (IC), CLI and chronic venous disease.

Elixir Medical Announces Commencement of INFINITY-SWEDEHEART Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Retrieved on: 
Tuesday, March 16, 2021
Medical devices, Health, Surgery, Clinical trials, Cardiology, Biotechnology, Medicine, Clinical medicine, Medical specialties, Interventional cardiology, Medical devices, Interventional radiology, Stent, Everolimus, Drug-eluting stent, Acute coronary syndrome, Paclitaxel, Percutaneous coronary intervention

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System , the first metallic coronary artery implant that adapts to vessel physiology.

Key Points: 
  • Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System , the first metallic coronary artery implant that adapts to vessel physiology.
  • The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES.
  • The INFINITY-SWEDEHEART study includes these complex patients with both Chronic Coronary Syndrome and Acute Coronary Syndrome.
  • Final 5-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice.

Growth Opportunities in the United States Drug Eluting Sinus Stent Market to 2025, Featuring Intersect ENT, Inc., Johnson & Johnson, Medtronic plc and Stryker Corporation

Retrieved on: 
Monday, March 15, 2021
Medical technology, Medicine, Interventional cardiology, Medical devices, Medical equipment, Interventional radiology, Stent, Stryker Corporation, DES, Drug-eluting stent, Steroid eluting sinus stent

The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e.

Key Points: 
  • The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e.
  • The report provides an in-depth analysis of the US drug eluting sinus stent (DESS) market by value.
  • The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region.
  • The key players of the drug eluting sinus stent (DESS) market are Intersect ENT, Inc., Medtronic plc, Stryker Corporation (Entellus Medical, Inc.), and Johnson & Johnson (Acclarent, Inc.) are also profiled with their financial information and respective business strategies.

United States Drug Eluting Sinus Stent (DESS) Market Size, Trends & Forecasts 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Health, Pharmaceutical, Interventional cardiology, Medical technology, Medicine, Medical devices, Medical specialties, Interventional radiology, Stent, DES, Cardiology, Drug-eluting stent, Steroid eluting sinus stent

The "The US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.
  • The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e.
  • The report provides an in-depth analysis of the US drug eluting sinus stent (DESS) market by value.
  • The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region.

Global Drug-device Combination Product Markets Report 2020: Technology Roadmap and Growth Opportunity - Drug-eluting Stents, Drug-eluting Contact Lens, Drug-eluting Bandages, & Orthopedic Implants

Retrieved on: 
Friday, February 5, 2021
Medical specialties, Medicine, Interventional cardiology, Clinical medicine, Medical devices, Cardiology, Restenosis, Surgery, Stent, Coronary stent, Drug-eluting stent, Percutaneous coronary intervention

3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity

Key Points: 
  • 3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity
    4.2 Future of Coronary Stents: Gene Eluting Stents to Overcome Restenosis and Late-stent Thrombosis Challenges
    4.6 Business Growth Opportunities - Patient Centric, Patient Specific, and Cost-effective Imaging Redefining Future of Therapy
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Elixir Medical Announces Outstanding 24-month Data for DynamX Coronary Bioadaptor System, Demonstrating Strong Safety With No Target Lesion Revascularization, Myocardial Infarction or Thrombosis Through 24 Months

Retrieved on: 
Wednesday, January 27, 2021
Health, Medical devices, Cardiology, Interventional cardiology, Medicine, Clinical medicine, Cardiology, Drug-eluting stent, Medical devices, Bioresorbable stent

The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating, having a radial strength similar to DES.

Key Points: 
  • The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating, having a radial strength similar to DES.
  • DynamX is the first metallic coronary artery implant to demonstrate positive adaptive remodeling of the vessel.
  • At 24 months, the bioadaptor continued to show no thrombosis, no MI, and no target vessel revascularization, which demonstrates a strong safety profile and excellent performance.
  • The 24-month clinical results presented this week demonstrate the sustained excellent clinical safety and effectiveness of the DynamX Bioadaptor, said Motasim Sirhan, Elixir Medical CEO.